Organogenesis CCO logs tax-withholding stock moves

Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026. The transactions, coded “F” and priced at $3.73 per share, were used to satisfy tax liabilities and left him with 628,418 shares held directly.

Insider Trade Summary

Exercise Price or Tax Liability: 43,959 shares

Exercise Price or Tax Liability 4 txns

Insider Grow Brian

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	3,346	$3.73	$12K
Exercise Price or Tax Liability	Class A Common Stock	18,910	$3.73	$71K
Exercise Price or Tax Liability	Class A Common Stock	10,559	$3.73	$39K
Exercise Price or Tax Liability	Class A Common Stock	11,144	$3.73	$42K

Holdings After Transaction: Class A Common Stock — 628,418 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Organogenesis (ORGO) Chief Commercial Officer Brian Grow report in this Form 4?

Brian Grow reported four tax-withholding dispositions of Organogenesis Class A common stock on February 15, 2026. These transactions, coded “F,” involved delivering shares at $3.73 each to satisfy tax obligations rather than open-market selling activity.

How many Organogenesis (ORGO) shares does Brian Grow hold after these transactions?

After the reported tax-withholding dispositions, Brian Grow directly holds 628,418 shares of Organogenesis Class A common stock. This figure reflects his ownership following the final February 15, 2026 transaction disclosed in the Form 4 filing data.

What does transaction code “F” mean in the Organogenesis (ORGO) Form 4?

Transaction code “F” indicates shares were disposed of to pay an exercise price or tax liability by delivering securities. In this Organogenesis filing, Brian Grow used Class A common stock at $3.73 per share to cover tax obligations, not to execute an open-market sale.

Were the Organogenesis (ORGO) transactions by Brian Grow open-market stock sales?

No, the Organogenesis transactions were tax-withholding dispositions coded “F,” not open-market sales. Brian Grow delivered shares of Class A common stock at $3.73 per share to satisfy tax liabilities associated with equity awards on February 15, 2026.

What price per share was used in Brian Grow’s Organogenesis (ORGO) tax-withholding dispositions?

Each of Brian Grow’s tax-withholding dispositions used a price of $3.73 per share for Organogenesis Class A common stock. This uniform price applied across the four February 15, 2026 transactions reported in the Form 4 data.

What role does Brian Grow hold at Organogenesis (ORGO) in this Form 4?

Brian Grow is identified as the Chief Commercial Officer of Organogenesis in the Form 4. The filing shows his officer status and reports his tax-withholding share dispositions and resulting direct ownership of 628,418 Class A common stock shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grow Brian

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/15/2026		F		3,346	D	$3.73	669,031	D
Class A Common Stock	02/15/2026		F		18,910	D	$3.73	650,121	D
Class A Common Stock	02/15/2026		F		10,559	D	$3.73	639,562	D
Class A Common Stock	02/15/2026		F		11,144	D	$3.73	628,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stacie S. Aarestad, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.